We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Anti-Adhesion Agent May Reduce Post-Surgical Infertility

By HospiMedica staff writers
Posted on 12 Nov 2007
A new study has found that a 4% Icodextrin solution was more effective in reducing the incidence of post-operative adhesions in patients undergoing gynecological laparoscopic adhesiolysis than lactated Ringer's solution (LRS). More...


Researchers at University of Sheffield (United Kingdom) and other institutions conducted a randomized, double-blinded trial that involved 402 patients who underwent gynecological laparoscopic surgery involving adhesiolysis at 16 sites in the United States. Two hundred and three patients were administered Adept adhesion reduction solution [4% Icodextrin Solution] during surgery and 199 patients were administered LRS. The Patients' primary diagnoses included pelvic pain, infertility, endometriosis, and known adhesions. A second follow-up laparoscopy was scheduled four to eight weeks later.

The results showed that among patients in the Adept group, more than 45% achieved clinical success--defined as the greater of a reduction in adhesions of at least three or 30% of sites lysed between the first and second laparoscopies--during the second physician observation compared to 35.6% in the LRS group. Among infertility patients, 52.9% of patients in the Adept group had a positive reduction in American Fertility Score (AFS), the standardized method to score and classify adhesions to the ovaries or fallopian tubes that may affect fertility, compared to 30.4% in the LRS group. The study was published in the November 2007 issue of Fertility and Sterility.

Adept adhesion reduction solution, a product of Vectura (Chippenham, UK), and Baxter International (Deerfield, Il, USA), is indicated for use intraperitoneally for the reduction of post-surgical adhesions in patients undergoing gynecological laparoscopic adhesiolysis. Adept is contraindicated in patients with known or suspected allergy to cornstarch based on polymers, such as icodextrin, with maltose or isomaltose intolerance, or with glycogen storage disease.

"Adhesions can take several days to form following surgery,” said Ron Lloyd, vice president of Baxter's biotherapeutics and regenerative medicine business. "Adept forms a fluid reservoir in the peritoneal cavity, that resides there during the critical period of adhesion formation, separating and minimizing contact between organs.”


Related Links:
University of Sheffield
Vectura
Baxter International

Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
New
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.